Dexlansoprazole

Trade Name:

Dexilant

Manufacturer/Distributor:

Takeda

1-888-825-3321, option 3

www.takedacanada.com

Classification:

Proton pump inhibitor

ATC Class:

A02BC--

Status:

active

Notice of Compliance (yyyy/mm/dd):

2010/07/22

Date Marketed in Canada (yyyy/mm/dd):

2010/07/26

Presentation:

Capsule, delayed release: 30 mg DIN: 02354950

Capsule, delayed release: 60 mg DIN: 02354969

Comments:

For healing of all grades of erosive esophagitis; for maintaining healing of erosive esophagitis; for treatment of heartburn associated with non-erosive GERD. The capsule has a dual delayed release formulation and contains two types of enteric-coated granules with different pH-dependent dissolution profiles. One type of granule releases dexlansoprazole in the proximal small intestine; the other releases the drug in the distal region of the small intestine several hours later.

Keywords:

gastroesophageal reflux

Keywords:

esophagitis

Keywords:

dexlansoprazole

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

Generic Name	Common Trade Name(s)	Classification	Date Marketed in Canada (yyyy/mm/dd)
Phosphate Effervescent	Phosphate Sandoz		2017/01/01
Aminophylline	Phyllocontin	Bronchodilator	2010
Doravirine	Pifeltro	NNRTI	2018/11/15
Alpelisib	Piqray	Antineoplastic agent	2020/03/11
Pomalidomide	Pomalyst	Antineoplastic agent; immunmodulator	2014/02/24
Tetracaine	Pontocaine (spinal anesthesia)	Local anesthetic
Ponesimod	Ponvory	Sphingosine 1-phosphate receptor modulator	2021/04/28
Dexmedetomidine	Precedex	Alpha-2 adrenergic agonist	2010/02/24
Vitamin C	Prevegyne	Gynecological antiinfectives and antiseptics	2011/01
Pneumococcal 13-valent conjugate vaccine	Prevnar 13	Vaccine	2010/03/17
Letermovir	Prevymis	Antiviral agent	2017/12/20
Lumiracoxib	Prexige	COX-2 inhibitor	2006/11
Darunavir	Prezista	Antiviral agent	2006
Desvenlafaxine	Pristiq	Antidepressant	2009/03/02
Buprenorphine	Probuphine	Opiate partial agonist	2018/04/18
Denosumab	Prolia	RANK Ligand inhibitor	2010/08/10
Propofol	Propofol Injection	Anesthetic, sedative	2010/06/01
Saxagliptin + dapagliflozin	Qtern	Oral antihyperglycemic agent	2018/03/20
Edaravone	Radicava	Treatment for amyotrophic lateral sclerosis	2019/10/29
Silodosin	Rapaflo	Alpha-1 adrenergic blocker	2012/03/05
Aliskiren and hydrochlorothiazide	Rasilez HCT	Renin inhibitor and diuretic	2009/09
Prucalopride	Resotran	Enterokinetic agent	2012/01/13
Cyclosporine	Restasis	Topical immunomodulator with anti-inflammatory effects	2010/10
Sildenafil citrate	Revatio IV	cGMP-Specific Phosphodiesterase Type 5 Inhibitor	2010/08/31
Lenalidomide	Revlimid	Antineoplastic agent
Eltrombopag	Revolade	Thrombopoietin receptor antagonist	2011/0404
Brexpiprazole	Rexulti	Antipsychotic agent	2017/04/20
Upadacitinib	Rinvoq	Disease-modifying antirheumatic agent	2020/01/16
Calcitriol	Rocaltrol oral solution	Vitamin D analogue
Ivermectin	Rosiver	Topical rosacea therapy	2015/05/25
Entrectinib	Rozlytrek	Antineoplastic agent
Rupatadine	Rupall	Antihistamine, second generation	2017/01/25
Semaglutide	Rybelsus	Incretin mimetic	2020/04/19
Tolvaptan	Samsca	Vasopressin V2 receptor antagonist	2011/09/22
Asenapine	Saphris	Atypical antipsychotic	2012/03/16
Isatuximab	Sarclisa	Antineoplastic agent, monoclonal antibody	2020/07/03